The drug is now in Phase 2 clinical trials in patients with Alzheimer’s and Fragile X syndrome.
Preclinical research found that the drug – called BPN14770 – deters the effects of amyloid beta, a hallmark protein of Alzheimer’s that is toxic to nerve cells.
BPN14770, under development by Tetra Therapeutics, could help activate these mechanisms that support nerve health and prevent dementia, even with the progression of Alzheimer’s.